Vertex Pharmaceuticals Incorporated (VIE:VRTX)

Market Cap	100.00B -5.3%
Revenue (ttm)	9.99B +10.3%
Net Income	3.13B
EPS	12.12
Shares Out	n/a
PE Ratio	31.93
Forward PE	22.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	21
Open	394.40
Previous Close	394.15
Day's Range	394.40 - 395.95
52-Week Range	313.80 - 474.60
Beta	n/a
RSI	51.41
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD